FGP
TEVA icon

Foyston, Gordon, & Payne’s Teva Pharmaceuticals TEVA Stock Holding History

Foyston, Gordon, & Payne’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-572,656
Closed -$26.3M – 78
2016
Q3 		$26.3M Sell
572,656
-21,925
-4% -$1.14M 5.09% 3
2016
Q2 		$29.9M Buy
594,581
+26,305
+5% +$1.4M 5.44% 2
2016
Q1 		$30.4M Sell
568,276
-969
-0.2% -$56.9K 5.66% 2
2015
Q4 		$37.4M Buy
569,245
+103,030
+22% +$6.37M 7.06% 1
2015
Q3 		$31.2M Sell
466,215
-183,986
-28% -$11.9M 5.81% 1
2015
Q2 		$38.4M Buy
650,201
+13,628
+2% +$841K 5.78% 1
2015
Q1 		$39.7M Buy
636,573
+10,571
+2% +$615K 5.85% 1
2014
Q4 		$20.9M Buy
626,002
+4,051
+0.7% +$226K 2.99% 9
2014
Q3 		$33.4M Sell
621,951
-52,937
-8% -$2.8M 4.8% 2
2014
Q2 		$35.4M Buy
674,888
+313,877
+87% +$16M 4.49% 1
2014
Q1 		$19.1M Sell
361,011
-474,988
-57% -$22M 2.35% 13
2013
Q4 		$33.5M Buy
835,999
+55,415
+7% +$2.18M 4.16% 2
2013
Q3 		$29.5M Buy
+780,584
New +$30.4M 3.85% 3

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Foyston, Gordon, & Payne's TEVA Position: Q4 2016 in Review

Foyston, Gordon, & Payne sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 572,656 shares — an estimated $26.3M sold.

Foyston, Gordon, & Payne first reported a position in TEVA in Q3 2013 and held it in 13 quarters. The position peaked at $39.7M in Q1 2015. 739 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

  • Foyston, Gordon, & Payne reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Foyston, Gordon, & Payne sold 572,656 Teva Pharmaceuticals shares in Q4 2016, an estimated $26.3M.
  • Foyston, Gordon, & Payne first reported a position in Teva Pharmaceuticals in Q3 2013 and held it in 13 quarters.
  • Foyston, Gordon, & Payne's Teva Pharmaceuticals position peaked at $39.7M in Q1 2015.
  • 739 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Foyston, Gordon, & Payne's 13F filing for Q4 2016, filed 13 Feb 2017.